Psilocybin
CTT Pharma Files 2 USA Patents and 2 Canadian Patents
Tampa, Florida, United States – The Newswire – October 12, 2022 – CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) is pleased to announce that we…
Tampa, Florida, United States – The Newswire – October 12, 2022 – CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) is pleased to announce that we have filed four new patents, two in the USA and two in Canada. These new patents offer Naturally-derived Wafer Formulations containing Analgesics and Micro emulsions. The strengthened and updated intellectual property focuses on wafer compositions incorporating a naturally-derived and unique type of nanoparticles loaded with analgesics. This naturally-derived technology is not limited to analgesics, but can also incorporate other Active Pharmaceutical Ingredients(APIs), Natural Health Ingredients(NHIs) and psychoactive compounds. Examples being, Nicotine, CBD, Cannabinoids, and Psilocybin to name a few.
Ryan Khouri, CEO of CTT Pharma stated that these patents will continue to strengthen and protect our technology in multiple ways. Including but not limited to a two stage absorption process and allowing for the taste from our dissolvable strips to last longer after the strip has dissolved. Mr. Khouri further states that, I’m excited that these newly filed patents will offer stronger and better layers of protection to our existing patents. We worked very hard on these newly filed patents and will continue to do the necessary research and development for this advancement in our technology. These additional patents would give CTT 5 Canadian Patents and 4 US Patents.
CTT will continue to update shareholders as more news becomes available.
www.cttpharmaceuticals.com
www.linkedin.com/in/ryan-khouri-679a251b7
Ryan Khouri at 813-606-0060
Copyright (c) 2022 TheNewswire - All rights reserved.
psilocybin psychoactive otc research-
Psychedelics1 week ago
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week ago
Going concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week ago
Are Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week ago
Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation1 week ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics1 week ago
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product